INTRODUCTION
Infliximab (IFX), a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is widely used in the treatment of inflammatory bowel disease (IBD) and other i n f l am m ator y c on d it i ons such as rheumatoid arthritis, spondylarthropathy and psoriatic diseases [1] [2] [3] [4] . The Food and Drug Administration (FDA) approved IFX in the United States only for administration via infusion at the dosage of 5 to 10 mg/Kg with an infusion time of 120 min and monitoring time of 2 hours thereafter [5] . Despite the proven efficacy of IFX therapy, the infusion is burdened by acute and delayed infusion reactions that occur within 24 hours or later, up to 14 days after treatment [6, 7] . Nevertheless, the incidence of acute infusion reactions, mostly mild or moderate, is 2.5-5.4% [8] and can be managed by slowing the speed or temporarily interrupting the infusion, supported by steroids and antihistamine drugs administration [9, 10] . Scheduled treatment and concomitant immunomodulators are generally considered to be protective J Gastrointestin Liver Dis, June 2015 Vol. 24 No 2: 165-170 factors against infusion reactions [11] . Moreover, infusion procedures are time-consuming for dedicated nursing staff and affect the social and family life, the work or studies of patients in about 15% of cases [11] . Shortening the infusion time, after a well-tolerated standard induction phase, has proven to be a practicable and safe expedient improving the compliance to IFX therapy, and this is now included in the Remicade TM package insert [5, 12] .
The present study was prospectively performed on IBD patients recruited from the hospital files with the primary aim of evaluating whether shortening the infusion time of IFX could have an impact on the quality of life (QoL) as compared with the standard infusion and the secondary aim of verifying the safety and tolerability of the one-hour infusion.
METHODS

All adult subjects affected by IBD (ulcerative colitis [UC] or
Crohn's disease [CD] ) who previously received IFX in our Unit were considered for the study. All patients naïve to any other biological therapy were enrolled and included in the study, after giving written informed consent. Patients unwilling or unable to participate in the study due to psychiatric or educational bias were excluded.
Demographic and clinical characteristics of the patients including sex, age, duration, location and extension of the disease, clinical activity score at the onset, notably the Mayo score for UC and Harvey-Bradshaw index for CD, body mass index (BMI) and co-administration of further immunomodulator drugs (azathioprine or steroids) were retrospectively collected and included in the file record of each patient. We considered disease activity at onset, since in all patients the disease activity scores indicated clinical, but not endoscopic remission at the time of administration of the questionnaire. The patients were divided into two groups, according to the infusion schedule used for IFX administration, i.e. 1-hour infusion with 1 hour of monitoring or the standard 2-hour time and subsequent monitoring phase of 2 hours. Patients in the 1-hour group underwent an infusion speed of 10 ml/h for the first 15 minutes, increasing the rate to 300 ml/h to complete it within 1 hour; whereas the 2-hours group received the drug according to the standard protocol. The nursing staff registered details on each patient and infusion (starting and ending time, infusion pump speed, number of previous infusions, necessity and type of premedication) and jointly with medical staff, recorded any adverse event during and after the infusion. All scheduled patients had a 5 mg/Kg dose of IFX every 2 months. The main criterion to shorten the infusion was the absence of IFX infusion-related adverse reactions (acute or delayed) during the previous three standard infusions. Prophylaxis prior to infusion was performed only in patients who showed adverse reactions.
Each patient who agreed to participate in the study was asked to answer a questionnaire about the quality of life (QoL) and to give written informed consent. The study patients filled out the questionnaire only once after enrollment. This procedure is in agreement with other studies investigating QoL in IBD patients [13] and was adopted because multiple evaluations per patient could be strongly affected by the remittent-recurrent course of the diseases. The collection and statistical interpretation of privacy data was performed according to Italian law, in order to ensure the anonymity of enrolled patients.
The questionnaire, derived from Van Assche et al. [11] and modified according to our purposes, was composed of six questions:
• Question 1 (Q1): How satisfied are you with the infusion therapy that you are receiving at our unit?
• Question 2 (Q2): How much impact do you believe that the infusion therapy has on the overall quality of your life?
• Question 3 (Q3): How much effect do you believe that the infusion therapy has on your work and/or school life?
• Question 4 (Q4): How much impact do you believe that the infusion therapy has on your social life (relationships with family and/or friends)?
• Question 5 (Q5): How much impact do you believe that the infusion therapy has on your sexual life?
• Question 6 (Q6): How much effect do you believe that the side effects that occurred as a result of the infusion therapy have had on your quality of life?
The patient was asked to answer according to a five points Likert scale, ranging from 1-5. In this scale, 1 indicated the best outcome and 5 the worst. No evaluation was drawn from the sum of all the scores.
Statistical analysis
Univariate analysis included two comparisons. In the first one, we compared demographic and clinical characteristics as well as QoL scores between the 1-hour and 2-hour groups; in the second one, we compared the same parameters in the two subgroups (UC versus CD) in the 1-hour group. For these comparisons, Student's t-test for unpaired measures or Fisher's exact test were used. In order to evaluate which factor could affect the QoL related answers depending on the short or conventional infusion time, we performed ordinal regression (multivariate analysis). We considered the answers to the questionnaire as dependent variables, and demographic and clinical characteristics of the patients as independent variables. A p value of less than 0.05 was considered significant. For those independent variables found to be statistically significant, Odds Ratios (OR) and 95% Confidence intervals (95% CI) were calculated. All statistical tests were 2-tailed and performed at the 5% level of significance. The author who performed the analysis was blinded to the groups and the meaning of the codes employed for the analysis. A second author then interpreted the results. Statistical analyses were performed using software SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.
RESULTS
A total of 105 patients undergoing IFX therapy were initially considered and 81 of them fulfilled the inclusion criteria. Figure 1 
Univariate analysis
The main demographic and clinical features of the patients are reported in Table I . Patients in the 2-hour group had a statistically higher rate of infusion reactions (56.3%) than in the 1-hour group (9 patients, 13.8%). These last 9 subjects were returned to the standard time according to the study design.
The QoL scores are illustrated in Table II . The results of the questionnaires demonstrated that the 2-hours infusion leads to a worse QoL in work and social life, and has a bad impact on the overall QoL. No differences were found in answers regarding the sexual life and perception of side effects.
The clinical traits of CD and UC in patients undergoing the 1-hour infusion were found to be very similar. The only differences concerned the age (UC >CD) and a slight worsening of social QoL in CD as compared to UC, as shown by the scores to Question 4 (p= 0.04).
Multivariate analysis
Ordinal regression showed that the general satisfaction with the services (Q1), regardless of the infusion time, was correlated with the presence of adverse events after the infusion (OR 0.165; 95% CI 0.067-0.263; p=0.04) and with the administration of further immunosuppressant drugs (OR 0.281; 95% CI 0.222-0.340; p=0.006).
According to the ordinal regression, the overall QoL (Q2) was poorly influenced by the age of the patient (OR 1.023), female sex (OR 2.04), severe disease activity score at onset (OR 7.242). On the other hand, pancolitis, when treated with IFX, was found to be associated with a good improvement in the QoL (OR 0.093). Finally, shortening the duration of the infusion to 1 hour determined a better QoL (OR 0.626), as displayed in Table III. The job QoL (Q3) showed that subjects undergoing the 1-h IFX infusion reported a better outcome in comparison to the 2-h infusion (OR 0.588; 95% CI 0.485-0.691; p=0.001).
Analyzing the data in the questionnaire regarding social QoL (Q4) the only independent variable determining a better QoL was shown to be the duration of the infusion: patients receiving the 1-h schedule had a good correlation with this parameter, as expressed by an OR 0.643 (95% CI 0.374-0.912; p=0.01). In this regard, previous reports showed that the IFX short infusion was safe and tolerated in a pediatric population [14] even at the double dosage of 10 mg/kg [15] . The criteria to reduce the time of infusion have been defined as the absence of IFX infusion-related adverse reactions (acute or delayed) during the previous three 2-h infusions; no significant adverse event at the last 1-h infusion [16] is required to continue with the shorter infusion time. These criteria explain the disparity in the size of the groups, even if patients had similar demographic characteristics despite this disproportion, as reported in Table 1 . Recently, a meta-analysis by Neef et al. [17] including 10 studies regarding IBD, rheumatoid arthritis, spondylarthopathy and psoriatic disease, reported a lower rate of infusion reactions in the 1-hour population compared with the standard infusion and this finding was confirmed by per protocol and per patient analysis; the same result was not obtained with an infusion time shorter than 45 minutes. Premedication administration is not uniformly documented in the published studies and does not seem to affect the different infusion time outcome. A similar result has been described for concomitant medications including one or more immunomodulators (mercaptopurine, methotrexate, azathioprine or leflunomide) [18] , ongoing steroids and primary disease (gastrointestinal, rheumatological and dermatological diseases). To our knowledge, there are no data in the literature on the degree of patient satisfaction comparing the standard versus 1-hour treatment regimen. Therefore, we designed a study to assess short infusion liking, using an anonymous questionnaire to avoid patient identification.
In our cohort of 81 patients, matched for age, years of illness, number of infusions and premedication, 80% were treated with 1-hour IFX due to the absence of side effects at the first three infusions. During the successive infusions, they presented a statistically lower rate of side effects compared to the group receiving the 2-hour infusion, thus confirming the safety of the procedure. Moreover, the short infusion had a better impact on the QoL including general, work and social life. Sexual life was not influenced by the different infusion time even if it was negatively correlated with older age, disease severity at onset, the administration of concomitant immunomodulators and presence of perianal disease. Conversely, long lasting illness improved the quality of sexual life, presumably in relation to the beneficial effect of therapy. In detail, in our study the OR value was 0.93, very close to 1. This means that only few patients with long lasting disease experienced an improvement in QoL. On the other hand, this point is widely confirmed by literature data in which psychosocial impairments are strongly associated with severe disease activity [19] , that means more medication, more outpatient consultations, more complications, including hospitalization or surgery.
At the sub-analysis, it should be observed that there were no differences between CD and UC patients' perception of the QoL regardless of the infusion time; the only difference was age (UC > CD). Therefore, a slight worsening of the social QoL in CD compared to UC, as shown by the scores to Question 4 (p= 0.04) may be explained by the younger age of CD patients, which presumably reflects a more intense social life.
According to the ordinal regression, the QoL was negatively influenced by the age of patients (OR 1.023), female sex (OR 
DISCUSSION
The main finding of the present study was a positive impact on the QoL of the 1-hour infusion of IFX as compared to the standard 2-h protocol, in a well-defined group of patients. Moreover, the study confirmed the safety of the procedure and good compliance. 2.04) and severe disease activity score at onset (OR 7.242). A severe disease activity at onset is a predictor of nonresponsiveness to first-line therapies. Therefore, an aggressive strategy with an early use of IFX (Top-down) could be useful to counteract the disease progression [20] . On the other hand, the total number of infusions (OR 0.891) was a marker of a good therapeutic outcome, indicating that the greater the number of infusions, the less the perception of adverse reactions.
Inflammatory bowel disease patients are used to living with the prospect of a progressive worsening of the QoL [21, 22] and this fear works on different levels, depending on the disease severity, with the final result negatively affecting the overall perception of the QoL. A low clinical activity, supported by a response to treatment, implies a better QoL and a greater enjoyment of social life, family and work. In this context, a reduced infusion time is a great opportunity to save time that patients can devote to themselves and to their activities.
Interestingly, the satisfaction with the service for the short infusion was negatively correlated with the occurrence of infusion adverse events (OR 0.165) and with the administration of further drugs (OR 0.281), but was not influenced by the number or the length of the infusions.
Possible limitations of the present study include the sample size, since it was a single-centre study, although the power of the statistical analysis may counteract this limitation. Furthermore, it is important to underline that the QoL is not only dependent on the clinical characteristics of the disease for each patient, because personal attitude and behaviour, social status, economic wealth, familial relationships and type of work may influence the QoL.
A possible bias of our study is the lack of patients without a history of side effects in the control group, i. e. with standard infusion time. However, our analysis was performed in patients undergoing the conventional or short infusion according to the current criteria.
CONCLUSION
The QoL of IBD patients remains a matter of care in overall IBD because these patients are strongly influenced just by being ill. In our experience, the 1-hour infusion is well tolerated, safe and very widespread in our infusion unit. Compared with the standard protocol, it shows fewer infusion reactions and it seems to lead to an improvement in the social, familial and work life. Nevertheless, this novel preliminary result needs to be confirmed by prospective studies comparing QoL in subjects without previous infusion side effects, randomly assigned to conventional or short infusion time IFX therapy.
